This inventor holds 37 USPTO granted patents and 4 published patent applications and 1 EPO patent, primarily in Microbial Diagnostics. Top assignees: Medical Diagnostic Laboratories, LLC, Medical Diagnostic Lab, LLC, Other. Active years: 2010-2020.
Location History:
- Belle Mead, NJ (US) (2011 - 2013)
- East Wiindsor, NJ (US) (2014)
- Hillsborough, NJ (US) (2010 - 2016)
- Belle Meade, NJ (US) (2018)
- East Windsor, NJ (US) (2012 - 2020)
Company Filing History:
35 out of 80 
1 out of 1 
1 out of 834,411 Years Active: 2010-2020
Areas of Expertise:
Title: Martin E. Adelson: Innovator in Medical Diagnostics
Introduction
Martin E. Adelson is a noted inventor based in East Windsor, NJ, USA, recognized for his significant contributions in the field of medical diagnostics. With an impressive total of 37 patents to his name, he has been at the forefront of innovative solutions in healthcare, particularly concerning antibiotic resistance.
Latest Patents
Among Adelson's latest inventions are patents focused on single nucleotide polymorphisms (SNPs) associated with community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). His discovery of novel polymorphisms in the penicillin-binding protein (pbp3) gene has led to the identification of G88A and/or G2047A SNPs, providing reliable biomarkers for detecting the presence of Methicillin Resistant (MRSA). The methodologies outlined in his patents include isolating biological samples from mammals, preferably humans, and testing for these SNPs, which are critical for screening subjects for CA-MRSA. These advancements represent a vital step in combating antibiotic resistance and improving patient diagnostics.
Career Highlights
Throughout his distinguished career, Martin E. Adelson has worked with notable institutions in the medical diagnostic field, including Medical Diagnostic Laboratories, LLC. His innovative work has significantly impacted diagnostic methodologies, leading to improved healthcare outcomes.
Collaborations
Adelson has collaborated with esteemed professionals, including Eli Mordechai and John G. Hoey, contributing to a dynamic exchange of ideas that has fostered further innovation in medical diagnostics. These partnerships underline the importance of teamwork in the advancement of healthcare technologies.
Conclusion
Martin E. Adelson continues to be a driving force in the field of medical diagnostics through his inventions and collaborations. His work in identifying biomarkers for antibiotic resistance is not only groundbreaking but essential in addressing healthcare challenges. With a portfolio of 37 patents, Adelson's contributions are a testament to his commitment to innovation and improving patient care.